Horizon Pharmaceuticals (HZNP) rose 12.8% for the week ended November 20, 2015. HZNP rose after it withdrew from acquiring DepoMed (DEPO).
Mylan (MYL) stock rose 6.4% for the week ended November 20, 2015. It went up on a couple of new drug launches and a share repurchase plan.
Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.
The PBV (price-to-book value) ratios of Sirona Dental Systems, Danaher Corporation, Align Technology, and Patterson Companies are 4.7x, 2.9x, 6.7x, and 3.2x, respectively.
After the release of Sirona Dental Systems’ (SIRO) 4Q15 earnings report, SIRO rose by 0.23% to close at $109.22 per share on November 20, 2015.
UnitedHealth Group’s reduced guidance led to market speculation regarding the individual exchange segment performances of companies such as Aetna and Cigna.
To limit future losses, UnitedHealth Group plans to evaluate the viability of the public health insurance exchange business in 1H16.
UnitedHealth Group updated its prior guidance for fiscal 2015 on its 3Q15 conference call, projecting earnings of about $6 per share.
The FDA has accepted Bristol-Myers Squibb’s (BMY) supplemental biologics license application, or sBLA, for Opdivo for the treatment of patients with advanced renal cell carcinoma.
BMY rose by ~1.3% to a closing price of $65.02 on November 16, 2015, after the FDA accepted Bristol-Myers Squibb’s sBLA for Opdivo for the treatment of patients with renal cell carcinoma.
The FDA has accepted BMY’s Opdivo supplemental biologics license application, or sBLA, for renal cell carcinoma, or RCC.
Opdivo, one of Bristol-Myers Squibb’s most important products, is expected to be one of its major revenue contributors in the next five years.
Orthopedic devices are devices used for the diagnosis and treatment of injuries or deformities of the musculoskeletal system, which includes bones, joints, ligaments, tendons, muscles, and nerves.
Traditionally, the United States has been home to the most advanced technological inventions in the medical device industry.
Though the medical device sector displays significant resilience towards changes in the economic environment, economic factors do impact short-term demand substantially.
In most countries, the approval process varies across different categories of devices classified as per their risk profiles.
The medical device industry consists of a few big manufacturing companies that dominate the market and a large number of small players.
Medical device companies are driven by innovation and inventions that involve high research and development (or R&D) costs.
Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.
The medical device industry in the US consists of a few big players and a large number of small and medium enterprises.